サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1513996

バイオシミラーの世界市場

Biosimilars

出版日
ページ情報
英文 193 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
バイオシミラーの世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

バイオシミラーの世界市場は2030年までに1,359億米ドルに達する見込み

2023年に378億米ドルと推定されたバイオシミラーの世界市場は、2030年には1,359億米ドルに達し、分析期間2023-2030年のCAGRは20.1%で成長すると予測されます。本レポートで分析したセグメントの1つである組換え非糖化タンパク質は、CAGR 20.5%を記録し、分析期間終了までに624億米ドルに達すると予想されます。組換え糖質化タンパク質セグメントの成長率は、分析期間中CAGR 20.5%と推定されます。

米国市場は推定107億米ドル、中国はCAGR19.6%で成長予測

米国のバイオシミラー市場は2023年に107億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに211億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは19.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ17.8%と16.7%と予測されています。欧州では、ドイツがCAGR約13.9％で成長すると予測されています。

バイオシミラー-主要動向と促進要因

バイオシミラーは、すでに承認されている参照用生物製剤と類似性が高く、安全性、純度、効力の点で大きな違いがない生物学的製剤です。これらの製品は生物に由来するため、従来の低分子医薬品よりも製造や開発が非常に複雑です。バイオシミラーは、がん、自己免疫疾患、糖尿病や関節リウマチなどの慢性疾患など、さまざまな疾患の治療に使用されています。バイオシミラーの開発には、包括的な分析試験、非臨床評価、臨床試験を通じて、基準製剤との類似性を実証する厳格なプロセスが含まれます。この治療により、バイオシミラーは、より高価な代替品と効果的に置き換えることができ、ヘルスケアシステムに大幅なコスト削減をもたらし、重要な治療への患者のアクセスを向上させることができます。このプロセスには、バイオシミラーがオリジナルの生物学的製剤と同じ作用機序、投与経路、剤形、強度を有することを証明し、同じ臨床的ベネフィットをもたらすことを保証することも含まれます。

バイオシミラー市場は、過去10年間に大きな成長と変貌を遂げてきました。米国、欧州、アジアなどの主要市場における規制の枠組みは、バイオシミラーの承認と採用をサポートするように発展してきました。欧州医薬品庁（EMA）や米国食品医薬品局（FDA）は、承認プロセスを合理化する強固なガイドラインを制定し、ヘルスケアプロバイダーや患者の信頼を醸成しています。これらのガイドラインでは、臨床的に意味のある差異がなく、バイオシミラーが参照生物学的製剤と類似していることを確認する包括的な比較試験を要求しています。さらに、いくつかのブロックバスター生物学的製剤の特許満了により、バイオシミラー医薬品の競争への扉が開かれました。製薬会社はバイオシミラーの開発と商業化に多額の投資を行っており、安定した品質と供給を確保するために高度な製造技術を活用しています。これには、最先端の細胞培養プロセス、精製技術、厳格な品質管理対策などが含まれます。また、バイオシミラー医薬品メーカーとヘルスケアプロバイダーとのコラボレーションやパートナーシップも、これらの製品の市場拡大や受容拡大に重要な役割を果たしています。

バイオシミラー市場の成長は、いくつかの要因によって牽引されています。バイオテクノロジーと製造プロセスの進歩により、バイオシミラーの生産効率と品質が向上し、基準生物製剤との競合が激化しています。慢性疾患の有病率の増加と費用対効果の高い治療に対する需要の高まりが、バイオシミラーの対応可能な市場を拡大しています。例えば、がん、糖尿病、自己免疫疾患などの罹患率が上昇を続ける中、手頃な治療オプションに対するニーズも高まっています。各国のヘルスケアコスト抑制策や有利な償還政策も、バイオシミラーの採用を後押ししています。政府や保険業者は、バイオシミラーがヘルスケア支出を削減する可能性があることをますます認識し、支援政策やインセンティブにつながっています。さらに、医療従事者や患者の間でバイオシミラーが受け入れられつつあることが、成功した臨床結果や実際のエビデンスに後押しされ、市場の成長を加速させています。バイオシミラー医薬品のポートフォリオ拡大や新興市場への参入など、製薬企業による戦略的な取り組みが市場拡大にさらに拍車をかけています。これらの企業はまた、処方者や患者の信頼と受容を築くために、大規模な教育キャンペーンに投資しています。さらに、バイオシミラーの特典と安全性について利害関係者を啓蒙する努力は、これらの救命治療薬がより多くの患者集団に行き渡ることを確実にし、市場への浸透を高めています。その結果、バイオシミラーは、高価な生物学的製剤に代わる、高品質で手頃な価格の治療薬を提供し、世界のヘルスケアにおいてますます重要な役割を果たす態勢を整えています。

調査対象企業の例（注目の46社）

  • Allergan Plc
  • Amgen Inc.
  • Biocon Ltd.
  • Biopartners GmbH
  • Boehringer Ingelheim International GmbH
  • Celltrion Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Fresenius Kabi
  • Intas Pharmaceuticals Ltd.
  • Mylan NV
  • Pfizer Inc.
  • Samsung Bioepis Co. Ltd.
  • Sandoz International GmbH
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP-6201

Global Biosimilars Market to Reach US$135.9 Billion by 2030

The global market for Biosimilars estimated at US$37.8 Billion in the year 2023, is expected to reach US$135.9 Billion by 2030, growing at a CAGR of 20.1% over the analysis period 2023-2030. Recombinant Non-glycosylated Proteins, one of the segments analyzed in the report, is expected to record a 20.5% CAGR and reach US$62.4 Billion by the end of the analysis period. Growth in the Recombinant Glycosylated Proteins segment is estimated at 20.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.7 Billion While China is Forecast to Grow at 19.6% CAGR

The Biosimilars market in the U.S. is estimated at US$10.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$21.1 Billion by the year 2030 trailing a CAGR of 19.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.8% and 16.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

Biosimilars - Key Trends and Drivers

Biosimilars are biologic medical products that are highly similar to already approved reference biologics, with no significant differences in terms of safety, purity, and potency. These products are derived from living organisms, making their production and development significantly more complex than traditional small-molecule drugs. Biosimilars are used to treat a range of diseases, including cancers, autoimmune disorders, and chronic conditions like diabetes and rheumatoid arthritis. The development of biosimilars involves a rigorous process of demonstrating similarity to the reference product through comprehensive analytical studies, non-clinical assessments, and clinical trials. This ensures that biosimilars can effectively replace their more expensive counterparts, providing significant cost savings for healthcare systems and increasing patient access to critical treatments. The process includes demonstrating that the biosimilar has the same mechanism of action, route of administration, dosage form, and strength as the original biologic, ensuring that it delivers the same clinical benefits.

The biosimilars market has witnessed substantial growth and transformation over the past decade. Regulatory frameworks in major markets such as the United States, Europe, and Asia have evolved to support the approval and adoption of biosimilars. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have established robust guidelines that streamline the approval process, fostering confidence among healthcare providers and patients. These guidelines require comprehensive comparative studies that confirm the biosimilar’s similarity to the reference biologic without clinically meaningful differences. Additionally, the patent expirations of several blockbuster biologics have opened the door for biosimilar competition. Pharmaceutical companies are investing heavily in the development and commercialization of biosimilars, leveraging advanced manufacturing technologies to ensure consistent quality and supply. This includes state-of-the-art cell culture processes, purification techniques, and stringent quality control measures. Collaborations and partnerships between biosimilar manufacturers and healthcare providers are also playing a critical role in expanding the market reach and acceptance of these products.

The growth in the biosimilars market is driven by several factors. Advances in biotechnology and manufacturing processes have enhanced the production efficiency and quality of biosimilars, making them more competitive with their reference biologics. The increasing prevalence of chronic diseases and the rising demand for cost-effective treatments are expanding the addressable market for biosimilars. For instance, as the incidence of conditions like cancer, diabetes, and autoimmune diseases continues to rise, so does the need for affordable treatment options. Healthcare cost containment measures and favorable reimbursement policies in various countries are also propelling the adoption of biosimilars. Governments and insurance providers are increasingly recognizing the potential of biosimilars to reduce healthcare expenditures, leading to supportive policies and incentives. Moreover, the growing acceptance of biosimilars among healthcare professionals and patients, driven by successful clinical outcomes and real-world evidence, is accelerating market growth. Strategic initiatives by pharmaceutical companies, such as expanding biosimilar portfolios and entering emerging markets, are further fueling the market's expansion. These companies are also investing in extensive educational campaigns to build trust and acceptance among prescribers and patients. Additionally, efforts to educate stakeholders about the benefits and safety of biosimilars are enhancing their market penetration, ensuring that these life-saving therapies reach a broader patient population. As a result, biosimilars are poised to play an increasingly important role in global healthcare, offering high-quality, affordable alternatives to costly biologic therapies.

Select Competitors (Total 46 Featured) -

  • Allergan Plc
  • Amgen Inc.
  • Biocon Ltd.
  • Biopartners GmbH
  • Boehringer Ingelheim International GmbH
  • Celltrion Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Fresenius Kabi
  • Intas Pharmaceuticals Ltd.
  • Mylan NV
  • Pfizer Inc.
  • Samsung Bioepis Co. Ltd.
  • Sandoz International GmbH
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Biosimilars - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Biotechnology Propel Growth in Biosimilars Market
    • Patent Expirations of Blockbuster Biologics Expand Addressable Market Opportunity for Biosimilars
    • Increasing Prevalence of Chronic Diseases Drives Demand for Cost-Effective Biosimilars
    • Regulatory Frameworks and Approvals Strengthen Business Case for Biosimilar Development
    • Growing Acceptance and Adoption of Biosimilars by Healthcare Providers Spur Market Growth
    • Technological Innovations in Manufacturing Processes Enhance Quality and Efficiency of Biosimilars
    • Real-World Evidence and Clinical Outcomes Drive Confidence and Demand for Biosimilars
    • Strategic Expansion into Emerging Markets Expands Global Reach of Biosimilars
    • Increasing Focus on Personalized Medicine Generates Demand for Specialized Biosimilars
    • Marketing Strategies Highlighting Cost and Clinical Benefits Drive Adoption of Biosimilars
    • Innovations in Cell Culture and Purification Techniques Strengthen Production of High-Quality Biosimilars
    • Growing Interest in Sustainable Manufacturing Practices Creates Opportunities in Biosimilar Production
    • Integration of Advanced Analytics and Big Data in Biosimilar Development Optimizes R&D Efforts
    • Rise in Investment and Funding for Biosimilar Research and Development Fuels Market Growth
    • Innovations in Biosimilar Delivery Mechanisms Generate Demand for User-Friendly Products
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Biosimilars Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Recombinant Non-glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Recombinant Non-glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Recombinant Glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Recombinant Glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Recombinant Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Recombinant Peptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Blood Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Blood Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Chronic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Chronic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Autoimmune Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Autoimmune Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2024 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 23: USA 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2024 & 2030
  • CANADA
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Canada 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2024 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2024 & 2030
  • JAPAN
    • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 28: Japan Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Japan 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2024 & 2030
    • TABLE 30: Japan Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 31: Japan 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2024 & 2030
  • CHINA
    • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: China 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2024 & 2030
    • TABLE 34: China Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 35: China 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2024 & 2030
  • EUROPE
    • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Biosimilars by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 37: Europe 7-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2024 & 2030
    • TABLE 40: Europe Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Europe 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2024 & 2030
  • FRANCE
    • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 42: France Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 43: France 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2024 & 2030
    • TABLE 44: France Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: France 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2024 & 2030
  • GERMANY
    • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 46: Germany Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Germany 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2024 & 2030
    • TABLE 48: Germany Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Germany 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2024 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Italy 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2024 & 2030
    • TABLE 52: Italy Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 53: Italy 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2024 & 2030
  • UNITED KINGDOM
    • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 54: UK Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 55: UK 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2024 & 2030
    • TABLE 56: UK Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: UK 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Rest of Europe 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2024 & 2030
    • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Rest of Europe 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2024 & 2030
    • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Asia-Pacific 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 66: Rest of World Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Rest of World 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2024 & 2030
    • TABLE 68: Rest of World Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of World 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2024 & 2030

IV. COMPETITION